Pfizer's stock falls 4% after saying it will not move to Phase 3 trial of weight-loss drug as twice-daily formation
Pfizer's drug helped patients lose weight but also caused nausea and diarrhea.
Source: marketwatch.com
Page 36 - Service Testing News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Service Testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Service Testing Today - Breaking & Trending Today
Pfizer's Weight Loss Drug Won't Enter a Phase 3 Trial. The Stock Drops.
'We believe an improved once-daily formulation of danuglipron could play an important role in the obesity treatment paradigm,' Pfizer says
Source: marketwatch.com
Health Up as Pfizer Slides -- Health Care Roundup
Health-care companies rose, but not by as much as the broad market, after a major setback for one entrant in the race to launch an effective weight-loss...
Source: marketwatch.com
Biora Therapeutics Shares Rise 64% After FDA Clears Application for Ulcerative Colitis Treatment
By Ben Glickman Shares of Biora Therapeutics rose late Thursday after the company received clearance from the U.S. Food and Drug Administration to use its...
Source: marketwatch.com
Fortrea Disputes Acerlyrin Statements Regarding Two Clinical Trials
By Chris Wack Fortrea said in a filing to the U.S. Securities and Exchange Commission that it disputes the accuracy of statements made by Acelyrin regarding...
Source: marketwatch.com